http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1315226-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91ce16ac3dbceb38cb5e6983c8c15a5a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-83 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-099 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-01 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 |
| filingDate | 1987-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1993-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ffd617bebcc4d25ad8116850389a651 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c79de7fc0f5f6cfaffdee93647eadfe6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe7ffc631f0f4df93f1bfe6a6e794377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ae9bbaff826850c831c35ed94fbaaf5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_961fcf242a7329bb227b568b0cb0bd01 |
| publicationDate | 1993-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1315226-C |
| titleOfInvention | Process for preparation of improved mutant strain of bordetella bronchiseptica useful for live attenuated vaccine for protection of b. bronchiseptica infection and live attenuatedar vaccine produced therefrom |
| abstract | ABSTRACT OF THE DISCLOSURE The present invention provides a process for preparation of a mutant strain of B. bronchiseptica having chromosomal genetic markers carrying at least temperature-sensitive (grown at 42°C), nalidixic acid-resistant and heat-labile dermonecrotic toxin producing ability negative markers preferable for preparation of live attenuated AR vaccine, which comprises subjecting a naturally isolated parent, wild or virulent strain of B. bronchiseptica, to growth at 42°C in the presence of nalidixic acid on a Bordet-gengou agar plate to induce mutation, isolating a mutant strain having the genetic markers of being at least temperature-sensitive (grown at 42°C), nalidixic acid-resistant and heat-labile dermonecrotic toxin negative, culturing the mutant strain of B. bronchiseptica resulting from the induced mutation on a Bordet-gengou agar plate containing nalidixic acid at 42°C, thereafer picking up an organism morphologically resembling a phase-I organism, and repeating the procedures of cultivation on the Bordet-gengou agar plate and picking up phase-I organisms. Also provided by the invention is a live attenuated AR vaccine for prophylaxis of B. bronchiseptica infection, which comprises B. bronchiseptica phase-I organisms of strain B-42 having chromosomal genetic markers of being temperature-sensitive (grown at 42°C), nalidixic acid-resistant and heat-labile dermonecrotic toxin negative. |
| priorityDate | 1986-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.